Which has higher valuation and earnings, ELMD or HYPR?

Electromed has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Electromed $71.75M 4.68 $5.15M $1.17 34.63 Hyperfine $11.40M 8.63 -$35.57M -$0.41 N/A

Is ELMD or HYPR more profitable?

Electromed has a net margin of 11.34% compared to Hyperfine's net margin of -226.88%. Electromed's return on equity of 15.71% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Electromed 11.34% 15.71% 13.37% Hyperfine -226.88% -98.83% -67.09%

Does the media prefer ELMD or HYPR?

In the previous week, Electromed had 1 more articles in the media than Hyperfine. MarketBeat recorded 2 mentions for Electromed and 1 mentions for Hyperfine. Hyperfine's average media sentiment score of 1.94 beat Electromed's score of -0.82 indicating that Hyperfine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Electromed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Hyperfine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation and earnings, HYPR or CV?

CapsoVision has higher revenue and earnings than Hyperfine. CapsoVision is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hyperfine $11.40M 8.63 -$35.57M -$0.41 N/A CapsoVision $13.55M 25.88 -$25.32M -$2.34 N/A

Is HYPR or CV more profitable?

CapsoVision has a net margin of -198.87% compared to Hyperfine's net margin of -226.88%. CapsoVision's return on equity of 0.00% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -226.88% -98.83% -67.09% CapsoVision -198.87% N/A -136.03%

Which has stronger valuation and earnings, HYPR or CARL?

Carlsmed has higher revenue and earnings than Hyperfine. Carlsmed is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hyperfine $11.40M 8.63 -$35.57M -$0.41 N/A Carlsmed $50.51M 6.19 -$29.63M -$2.51 N/A

Is HYPR or CARL more profitable?

Carlsmed has a net margin of -57.76% compared to Hyperfine's net margin of -226.88%. Carlsmed's return on equity of -60.74% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -226.88% -98.83% -67.09% Carlsmed -57.76% -60.74% -29.84%

Does the media prefer HYPR or CARL?

In the previous week, Carlsmed had 1 more articles in the media than Hyperfine. MarketBeat recorded 2 mentions for Carlsmed and 1 mentions for Hyperfine. Hyperfine's average media sentiment score of 1.94 beat Carlsmed's score of -0.12 indicating that Hyperfine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Carlsmed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HYPR or TMCI?

In the previous week, Treace Medical Concepts had 5 more articles in the media than Hyperfine. MarketBeat recorded 6 mentions for Treace Medical Concepts and 1 mentions for Hyperfine. Hyperfine's average media sentiment score of 1.94 beat Treace Medical Concepts' score of 0.83 indicating that Hyperfine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Treace Medical Concepts 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SGHT or HYPR more profitable?

Sight Sciences has a net margin of -46.83% compared to Hyperfine's net margin of -226.88%. Sight Sciences' return on equity of -52.34% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Sight Sciences -46.83% -52.34% -28.49% Hyperfine -226.88% -98.83% -67.09%

Does the media prefer SGHT or HYPR?

In the previous week, Sight Sciences and Sight Sciences both had 1 articles in the media. Hyperfine's average media sentiment score of 1.94 beat Sight Sciences' score of 0.00 indicating that Hyperfine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperfine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Hyperfine (HYPR) Competitors

$0.99 +0.01 (+1.32%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 -0.01 (-0.75%)

As of 05:02 PM Eastern

Compare

HYPR vs. ELMD, CV, CARL, TMCI, and SGHT

Should you buy Hyperfine stock or one of its competitors? MarketBeat compares Hyperfine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hyperfine include Electromed (ELMD), CapsoVision (CV), Carlsmed (CARL), Treace Medical Concepts (TMCI), and Sight Sciences (SGHT). These companies are all part of the "medical equipment" industry.

How does Hyperfine compare to Electromed?

Electromed (NYSE:ELMD) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

40.8% of Electromed shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 10.5% of Electromed shares are held by company insiders. Comparatively, 26.3% of Hyperfine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Electromed has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Hyperfine has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Electromed has a net margin of 11.34% compared to Hyperfine's net margin of -226.88%. Electromed's return on equity of 15.71% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Hyperfine	-226.88%	-98.83%	-67.09%

In the previous week, Electromed had 1 more articles in the media than Hyperfine. MarketBeat recorded 2 mentions for Electromed and 1 mentions for Hyperfine. Hyperfine's average media sentiment score of 1.94 beat Electromed's score of -0.82 indicating that Hyperfine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Electromed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Hyperfine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Electromed currently has a consensus target price of $37.50, suggesting a potential downside of 7.45%. Hyperfine has a consensus target price of $1.78, suggesting a potential upside of 79.88%. Given Hyperfine's higher probable upside, analysts plainly believe Hyperfine is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Electromed has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	4.68	$5.15M	$1.17	34.63
Hyperfine	$11.40M	8.63	-$35.57M	-$0.41	N/A

Summary

Electromed beats Hyperfine on 10 of the 15 factors compared between the two stocks.

How does Hyperfine compare to CapsoVision?

Hyperfine (NASDAQ:HYPR) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

In the previous week, Hyperfine had 1 more articles in the media than CapsoVision. MarketBeat recorded 1 mentions for Hyperfine and 0 mentions for CapsoVision. Hyperfine's average media sentiment score of 1.94 beat CapsoVision's score of 0.00 indicating that Hyperfine is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperfine	Very Positive
CapsoVision	Neutral

CapsoVision has a net margin of -198.87% compared to Hyperfine's net margin of -226.88%. CapsoVision's return on equity of 0.00% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
CapsoVision	-198.87%	N/A	-136.03%

Hyperfine currently has a consensus target price of $1.78, suggesting a potential upside of 79.88%. CapsoVision has a consensus target price of $8.50, suggesting a potential upside of 21.08%. Given Hyperfine's higher probable upside, analysts clearly believe Hyperfine is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

15.0% of Hyperfine shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by company insiders. Comparatively, 2.3% of CapsoVision shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CapsoVision has higher revenue and earnings than Hyperfine. CapsoVision is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	8.63	-$35.57M	-$0.41	N/A
CapsoVision	$13.55M	25.88	-$25.32M	-$2.34	N/A

Summary

Hyperfine beats CapsoVision on 9 of the 16 factors compared between the two stocks.

How does Hyperfine compare to Carlsmed?

Hyperfine (NASDAQ:HYPR) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Hyperfine currently has a consensus target price of $1.78, indicating a potential upside of 79.88%. Carlsmed has a consensus target price of $18.75, indicating a potential upside of 63.04%. Given Hyperfine's higher probable upside, research analysts clearly believe Hyperfine is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Carlsmed has higher revenue and earnings than Hyperfine. Carlsmed is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	8.63	-$35.57M	-$0.41	N/A
Carlsmed	$50.51M	6.19	-$29.63M	-$2.51	N/A

In the previous week, Carlsmed had 1 more articles in the media than Hyperfine. MarketBeat recorded 2 mentions for Carlsmed and 1 mentions for Hyperfine. Hyperfine's average media sentiment score of 1.94 beat Carlsmed's score of -0.12 indicating that Hyperfine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Carlsmed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Carlsmed has a net margin of -57.76% compared to Hyperfine's net margin of -226.88%. Carlsmed's return on equity of -60.74% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
Carlsmed	-57.76%	-60.74%	-29.84%

15.0% of Hyperfine shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 12.9% of Carlsmed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Carlsmed beats Hyperfine on 8 of the 15 factors compared between the two stocks.

How does Hyperfine compare to Treace Medical Concepts?

Hyperfine (NASDAQ:HYPR) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Hyperfine has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	8.63	-$35.57M	-$0.41	N/A
Treace Medical Concepts	$212.69M	1.29	-$59M	-$0.97	N/A

Hyperfine has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

Hyperfine presently has a consensus target price of $1.78, suggesting a potential upside of 79.88%. Treace Medical Concepts has a consensus target price of $4.97, suggesting a potential upside of 17.49%. Given Hyperfine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Hyperfine is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Treace Medical Concepts had 5 more articles in the media than Hyperfine. MarketBeat recorded 6 mentions for Treace Medical Concepts and 1 mentions for Hyperfine. Hyperfine's average media sentiment score of 1.94 beat Treace Medical Concepts' score of 0.83 indicating that Hyperfine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Treace Medical Concepts	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Treace Medical Concepts has a net margin of -29.44% compared to Hyperfine's net margin of -226.88%. Treace Medical Concepts' return on equity of -67.04% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
Treace Medical Concepts	-29.44%	-67.04%	-30.28%

Summary

Hyperfine beats Treace Medical Concepts on 10 of the 16 factors compared between the two stocks.

How does Hyperfine compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Sight Sciences presently has a consensus price target of $8.25, indicating a potential upside of 68.02%. Hyperfine has a consensus price target of $1.78, indicating a potential upside of 79.88%. Given Hyperfine's higher possible upside, analysts clearly believe Hyperfine is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Hyperfine has lower revenue, but higher earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	3.45	-$38.43M	-$0.71	N/A
Hyperfine	$11.40M	8.63	-$35.57M	-$0.41	N/A

In the previous week, Sight Sciences and Sight Sciences both had 1 articles in the media. Hyperfine's average media sentiment score of 1.94 beat Sight Sciences' score of 0.00 indicating that Hyperfine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hyperfine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 30.4% of Sight Sciences shares are owned by insiders. Comparatively, 26.3% of Hyperfine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sight Sciences has a net margin of -46.83% compared to Hyperfine's net margin of -226.88%. Sight Sciences' return on equity of -52.34% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
Hyperfine	-226.88%	-98.83%	-67.09%

Sight Sciences has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market. Comparatively, Hyperfine has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Summary

Sight Sciences beats Hyperfine on 9 of the 15 factors compared between the two stocks.

Get Hyperfine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYPR vs. The Competition

Export

Metric	Hyperfine	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$98.42M	$7.19B	$6.81B	$12.41B
Dividend Yield	N/A	1.32%	2.67%	9.39%
P/E Ratio	-2.42	49.84	27.00	24.19
Price / Sales	8.63	50.65	517.85	93.08
Price / Cash	N/A	26.91	26.68	47.25
Price / Book	2.36	6.94	10.67	6.26
Net Income	-$35.57M	$162.27M	$3.60B	$331.76M
7 Day Performance	-4.67%	-1.21%	-0.37%	-1.10%
1 Month Performance	-38.04%	-2.30%	1.80%	-1.29%
1 Year Performance	2.32%	5.52%	25.50%	18.84%

Hyperfine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYPR Hyperfine	3.2999 of 5 stars	$0.99 +1.3%	$1.78 +79.9%	+6.3%	$98.42M	$11.40M	N/A	190	Positive News
ELMD Electromed	0.634 of 5 stars	$44.34 -3.6%	$37.50 -15.4%	+124.2%	$367.14M	$71.75M	59.12	160	Positive News
CV CapsoVision	1.6809 of 5 stars	$6.36 +2.3%	$8.50 +33.6%	+48.4%	$317.75M	$13.55M	N/A	90	Positive News
CARL Carlsmed	2.2964 of 5 stars	$10.80 -10.8%	$18.75 +73.6%	N/A	$293.54M	$50.51M	N/A	100	Analyst Downgrade High Trading Volume
TMCI Treace Medical Concepts	3.6363 of 5 stars	$4.44 -3.1%	$4.77 +7.4%	-25.1%	$288.02M	$212.69M	N/A	250

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYPR) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperfine (HYPR) Competitors

HYPR vs. ELMD, CV, CARL, TMCI, and SGHT

How does Hyperfine compare to Electromed?

Summary

How does Hyperfine compare to CapsoVision?

Summary

How does Hyperfine compare to Carlsmed?

Summary

How does Hyperfine compare to Treace Medical Concepts?

Summary

How does Hyperfine compare to Sight Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPR vs. The Competition

Hyperfine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperfine (HYPR) Competitors

HYPR vs. ELMD, CV, CARL, TMCI, and SGHT

How does Hyperfine compare to Electromed?

Do insiders & institutionals believe in ELMD or HYPR?

Which has more volatility and risk, ELMD or HYPR?

Is ELMD or HYPR more profitable?

Does the media prefer ELMD or HYPR?

Do analysts rate ELMD or HYPR?

Which has higher valuation and earnings, ELMD or HYPR?

Summary

How does Hyperfine compare to CapsoVision?

Does the media refer more to HYPR or CV?

Is HYPR or CV more profitable?

Do analysts prefer HYPR or CV?

Do insiders & institutionals hold more shares of HYPR or CV?

Which has stronger valuation and earnings, HYPR or CV?

Summary

How does Hyperfine compare to Carlsmed?

Do analysts rate HYPR or CARL?

Which has stronger valuation and earnings, HYPR or CARL?

Does the media prefer HYPR or CARL?

Is HYPR or CARL more profitable?

Do insiders & institutionals believe in HYPR or CARL?

Summary

How does Hyperfine compare to Treace Medical Concepts?

Which has stronger valuation and earnings, HYPR or TMCI?

Which has more risk and volatility, HYPR or TMCI?

Do analysts rate HYPR or TMCI?

Do insiders and institutionals believe in HYPR or TMCI?

Does the media refer more to HYPR or TMCI?

Is HYPR or TMCI more profitable?

Summary

How does Hyperfine compare to Sight Sciences?

Do analysts recommend SGHT or HYPR?

Which has better valuation & earnings, SGHT or HYPR?

Does the media prefer SGHT or HYPR?

Do insiders and institutionals believe in SGHT or HYPR?

Is SGHT or HYPR more profitable?

Which has more volatility & risk, SGHT or HYPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPR vs. The Competition

Hyperfine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools